A Double-Blind Crossover, Placebo-Controlled Study of the Adenosine A2A Antagonist Theophylline in Parkinson's Disease

2002 ◽  
Vol 25 (1) ◽  
pp. 25-31 ◽  
Author(s):  
Jaime Kulisevsky ◽  
Manel Barbanoj ◽  
Alexandre Gironell ◽  
Rosa Antonijoan ◽  
Miquel Casas ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Controlled Study ◽  
Double Blind ◽  
Adenosine A2a

A double-blind, placebo-controlled study of intranasal apomorphine spray as a rescue agent for off-states in Parkinson's disease

1998 ◽  
Vol 13 (5) ◽  
pp. 782-787 ◽  
Author(s):  
Richard B. Dewey ◽  
Demetrius M. Maraganore ◽  
J. Eric Ahlskog ◽  
Joseph Y. Matsumoto
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Rescue Agent

A New Perspective in the Treatment of Parkinson’s Disease Psychosis

US Neurology ◽  
2016 ◽  
Vol 12 (02) ◽  
pp. 93
Author(s):  
Rajesh Pahwa ◽  
Kelly E Lyons ◽  
◽  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Neuropsychiatric Symptoms ◽  
Unmet Need ◽  
Controlled Study ◽  
Psychotic Symptoms ◽  
Dopamine Antagonists ◽  
Motor Symptoms ◽  
Double Blind ◽  
Good Tolerability

Neuropsychiatric symptoms, such as psychosis, are well described in Parkinson’s disease (PD); most appear to be due to disease pathology with exacerbation caused by dopaminergic treatment. More than 50% of patients with PD develop psychosis at some point throughout their disease course. Clinicians need to routinely assess patients with PD for psychotic symptoms, particularly hallucinations. Treatment of psychotic symptoms in PD is an unmet need as there are currently no US Food and Drug Administration (FDA) approved medications specifically for PD psychosis (PDP). Current treatments for PDP have been adapted from dopamine antagonists used to treat psychosis in other conditions, such as schizophrenia. Typical antipsychotics, as well as some atypical antipsychotics, worsen PD motor symptoms due to blockade of dopamine D2 receptors. Quetiapine and clozapine have been studied in PDP and are the most commonly used treatments for PDP. Clozapine has been shown to be effective; however, regular bloodwork is required, while data for quetiapine are inconsistent. Pimavanserin, a highly selective serotonin (5HT2A subtype) receptor inverse agonist, is not associated with motor worsening in PDP patients due to the absence of dopamine blockade. In a double-blind, placebo-controlled study, pimavanserin showed significant improvement in moderate to severe psychosis compared to placebo, with good tolerability and without worsening of PD motor symptoms. These data suggest that pimavanserin is a safe and efficacious treatment for PDP psychosis and could be a potential new treatment option for PDP.

scholarly journals A Double-Blind, Randomized, Placebo and Active-Controlled Study of Nebicapone for the Treatment of Motor Fluctuations in Parkinson's Disease

2010 ◽  
Vol 16 (6) ◽  
pp. 337-347 ◽  
Author(s):  
Joaquim J. Ferreira ◽  
Olivier Rascol ◽  
Werner Poewe ◽  
Cristina Sampaio ◽  
José-Francisco Rocha ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Motor Fluctuations ◽  
Controlled Study ◽  
Double Blind
Sign in / Sign up

Export Citation Format

Share Document